Literature DB >> 9777832

Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.

M Sudlow1, R Thomson, B Thwaites, H Rodgers, R A Kenny.   

Abstract

BACKGROUND: Anticoagulants are effective in the prevention of stroke in atrial fibrillation and flutter (AF). We aimed to find out the prevalence of AF in the UK and to estimate the proportion of patients with AF who might benefit from anticoagulation.
METHODS: We screened with electrocardiography a random sample of 4843 people from the community aged 65 years and older for AF. Participants with AF had further investigations to identify risk factors for stroke and contraindications to anticoagulants. We used three sets of criteria to assess risk and eligibility for anticoagulation.
FINDINGS: 228 (4.7%) participants had AF. According to analyses derived from risk stratifications based on the Stroke Prevention in Atrial Fibrillation (SPAF) study 61% of these patients would have benefited from anticoagulation, 49% according to pooled analysis of trial results, and 41% according to the inclusion criteria for the SPAF 3 study. Anticoagulants were used by 1114 (23%) of all patients and were least used among elderly women, who may be the most likely to benefit. Echocardiography would be useful to assess the need for anticoagulation only in patients younger than 75 years with no contraindications to treatment and no clinical risk factors for stroke.
INTERPRETATION: Anticoagulants seem to be underused and misdirected in treatment of AF, according to various criteria. Efforts to promote and support wider and more appropriate use of anticoagulants would seem to be justified, and should decrease the incidence of stroke amongst elderly patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9777832     DOI: 10.1016/S0140-6736(98)01401-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  83 in total

1.  Using anticoagulation or aspirin to prevent stroke. Research was methodologically flawed.

Authors:  S J Ellis; R Hans
Journal:  BMJ       Date:  2000-04-08

2.  Anticoagulation for patients with atrial fibrillation and risk factors for stroke. Warfarin reduces the risk by two thirds, but doctors still aren't prescribing it enough.

Authors:  S J Connolly
Journal:  BMJ       Date:  2000-05-06

3.  Anticoagulation to prevent stroke in atrial fibrillation. It's still not clear whether results in secondary care translate to primary care.

Authors:  D A Fitzmaurice; J Mant; E T Murray; F D Hobbs
Journal:  BMJ       Date:  2000-11-04

4.  Anticoagulation for patients with atrial fibrillation. Editorial may have overinterpreted data.

Authors:  N Dudley
Journal:  BMJ       Date:  2000-09-09

Review 5.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 6.  Clinical pharmacology and therapeutics into the future.

Authors:  Michael D Rawlins
Journal:  Br J Clin Pharmacol       Date:  2003-05       Impact factor: 4.335

7.  Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.

Authors:  Margaret C Fang; Daniel E Singer; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Alan S Go
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

Review 8.  Antithrombotic treatment in atrial fibrillation.

Authors:  L Kalra; G Y H Lip
Journal:  Heart       Date:  2006-09-04       Impact factor: 5.994

9.  Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study).

Authors:  H Völler; J Glatz; U Taborski; A Bernardo; C Dovifat; K Heidinger
Journal:  Z Kardiol       Date:  2005-03

10.  Rapid access arrhythmia clinic for the diagnosis and management of new arrhythmias presenting in the community: a prospective, descriptive study.

Authors:  J L Martins; K F Fox; D A Wood; D C Lefroy; T J Collier; N S Peters
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.